Recurrent or Metastatic Cervical Cancer (r/mCC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

If cervical cancer is discovered or returns after initial treatment with surgery, radiation, and/or chemotherapy, it is considered to have recurred or recurred. About one-third of diagnoses of non-small cell lung cancer (NSCLC) are localized advanced. In all of the world's female populations, cervical cancer is the third most common cancer. Cervical cancer is the second most prevalent cancer in developing countries, but it ranks only tenth in developed countries in terms of cancer recurrence rates. Depending on the disease's stage, different treatments are used for cervical cancer. When treating early invasive cancer, surgery is the preferred method. The current gold standard of care for more severe cases is radiation and chemotherapy. Patients with metastatic disease may experience symptom relief from chemotherapy or radiation therapy. Multidisciplinary approaches are frequently necessary for the treatment of cervical cancer.

Description

If cervical cancer is discovered or returns after initial treatment with surgery, radiation, and/or chemotherapy, it is considered to have recurred or recurred cervical cancer. About one-third of non-small cell lung cancer (NSCLC) diagnoses are localized advanced. Depending on the patient's type of treatment and the location of the recurrence, the course of treatment for cervical cancer recurrence will vary. Depending on whether they have had radiation before or not, some patients with cervical cancer that return to the pelvis may require additional surgery or radiation. Treatment for recurrent ectopic cervical cancer can be challenging. After a woman has finished her initial treatment, cervical cancer can come back occasionally. All cancer types are intended to be cured by treatment, but occasionally cancer cells cannot be found, or new ones develop. As a result, the cancer may come back in or near the cervix or in other areas of the body. Due to this, doctors typically conduct frequent follow-up exams to carefully monitor cervical cancer survivors. The majority of cancers are histologically classified as squamous cell carcinoma (SCC), adenocarcinoma, and adenocarcinoma. Seventy%, twenty-five%, and three to five% of all cervical cancers. Small cell carcinomas and neuroendocrine tumors are examples of rare tissues.

Recurrent or Metastatic Cervical Cancer (r/mCC) (Epidemiology)

In all of the world's female populations, cervical cancer is the third most common cancer. Cervical cancer is the second most common cancer in developing countries, but it is only the tenth most common cancer in developed countries, indicating that recurrence rates are very different between the two. Similar to how cervical cancer is not even among the top ten causes of death from cancer in developed countries, it is the second leading cause of cancer-related death among women in developing nations. In the United States, cases of cervical cancer are comparatively uncommon. Over the past several decades, there has been a steady decline in the incidence of cervical cancer in the United States; for instance, since 2004, this indicator has decreased by 21% per year for women under 50 and by 31% per year for women over 50. This pattern is brought on by widespread Pap test screening. In many developing nations, however, the incidence of cervical cancer is still rising. In 2022, the American Cancer Society (ACS) predicts that 14,100 new cases of cervical cancer will be discovered in the country. Internationally, more than 500,000 new cases are diagnosed each year: incidence rates range widely, from 4 per 100,000 people per year in West Asia to 34 per 100,000 women in East Africa. The incidence of cervical cancer ranges from 4 to 10 cases in industrialized nations with well-established cytology programs. 100,000 women. Between 1980 and 2010, Forouzanfar et al. conducted an annual assessment of cervical cancer by age in 187 nations. With an annual growth rate of 0.6%, the incidence of cervical cancer increased from 378,000 cases annually in 1980 to 454,000 cases annually in 2010. Cervical cancer deaths have decreased, but in 2010 the disease claimed the lives of 200,000 people; in developing nations, 46,000 of these women were aged 15 to 49 and 109,000 were 50 or older. According to the US Centers for Disease Control and Prevention (CDC), advanced cervical cancer discovered during screening for colon, rectal, breast, and cervical cancer was most common in women aged 50 to 79 years old in the US. Country. year. But cervical cancer can be found in any woman of childbearing age.

Recurrent or Metastatic Cervical Cancer (r/mCC) -Current Market Size & Forecast Trends

The market for recurrent or metastatic cervical cancer (r/mCC) is projected to grow steadily, with the cervical cancer market size reaching approximately USD 405.6 million in 2023 and expected to increase to around USD 583.4 million by 2034, reflecting a compound annual growth rate (CAGR) of 3.36% during this period. The growth is driven by advancements in treatment options, particularly the increasing adoption of immunotherapies and targeted therapies, alongside heightened awareness and screening efforts. Recent developments, such as the FDA's approval of TIVDAK (tisotumab vedotin-tftv) for r/mCC, signify significant progress in treatment efficacy and patient outcomes. Overall, the r/mCC market is well-positioned for growth through 2035, driven by ongoing research and the introduction of novel therapeutic strategies.

The stage of the disease affects how cervical cancer is treated. For early-stage invasive cancer, surgery is the treatment of choice. The current standard of care for more severe cases is chemotherapy and radiation. Patients with metastatic disease who receive chemotherapy or radiation therapy can experience symptom relief. Multidisciplinary treatment is frequently necessary for cervical cancer. An intravaginal dose of 5-fluorouracil (5-FU) at a concentration of 5% was found to be effective in treating cervical intraepithelial neoplasia (CIN) in a prospective, nonrandomized, controlled trial involving 60 women. At 6-month follow-up, 26 of 28 women (93%) who received 5-FU had disease regression, as opposed to 15 of 27 women (56%) in the control-only group. At 6-month follow-up, 14 of 28 patients in the treatment group had normal cervical biopsies, normal Pap smears, and negative HPV tests, compared to 6 of 17 patients in the control group. It was safe to use topical 5-FU. After the initial surgical procedure, radiation therapy and monotherapy should be used to treat pelvic recurrences, and combination chemotherapy should be used to treat recurrences at other sites. If a central pelvic recurrence develops after radiation therapy, it should be treated with a modified radical hysterectomy or pelvic dilation (if the recurrence is less than 2 cm). When the tumor was found to be platinum-sensitive, a disease-free period of more than 16 months was taken into account for diseases that returned after chemotherapy. Chemotherapy combined with the drugs cisplatin, platinum, and paclitaxel is the usual course of treatment in these cases. The NCCN advises docetaxel, gemcitabine, ifosfamide, 5-fluorouracil, mitomycin, irinotecan, and topotecan as potential second-line treatment candidates in addition to pemetrexed and phenolipin (grade 3 recommendation) (grade 2B recommendation). Additionally, bevacizumab may be used alone.

Report Highlights

Recurrent or Metastatic Cervical Cancer (r/mCC) - Current Market Trends

Recurrent or Metastatic Cervical Cancer (r/mCC) - Current & Forecasted Cases across the G8 Countries

Recurrent or Metastatic Cervical Cancer (r/mCC) - Market Opportunities and Sales Potential for Agents

Recurrent or Metastatic Cervical Cancer (r/mCC) - Patient-based Market Forecast to 2035

Recurrent or Metastatic Cervical Cancer (r/mCC) - Untapped Business Opportunities

Recurrent or Metastatic Cervical Cancer (r/mCC) - Product Positioning Vis-a-vis Competitors' Products

Recurrent or Metastatic Cervical Cancer (r/mCC) - KOLs Insight